Codexis had earlier filed an S-1 in April 2008 anticipation of an IPO then; the company withdrew the registration in September 2008 in light of the collapsing economy.

Codexis’ objective is to be the leading provider of optimized biocatalyst-enabled solutions across a wide range of industries. Key elements of its strategy are:

• Become a leading biocatalyst supplier to the advanced biofuels market. Its primary development efforts are focused on producing biocatalysts that can enable Shell to become a global leader in the advanced biofuels market. Shell has expanded its collaboration with Codexis twice. (Earlier post.)

• Expand into new bioindustrial markets. Codexis is actively pursuing opportunities in other bioindustrial markets, including through self-funded research in carbon management and the pursuit of funded collaborations in carbon management, water treatment and chemicals. It has the right to use the intellectual property developed in its collaboration with Shell in fields outside of fuels and related products.

• Continue growing its pharmaceutical business. The company intends to pursue new collaborations in the pharmaceutical industry to integrate products and services more deeply into drug development and manufacturing processes for clinical stage and commercially approved pharmaceutical products. As part of that effort, its will continue to aggressively market its Codex Biocatalyst Panels to pharmaceutical companies to demonstrate the capabilities of the technology platform.

• Secure access to additional production capacity. To increase biocatalyst manufacturing capacity and establish secondary supply sources, Codexis is working to establish long-term supply contracts with contract manufacturers and are evaluating whether to invest in our own manufacturing capabilities.

• Expand its business and technology platform through the addition of new technologies, products or businesses. In the past, it has expanded its business by acquiring companies with synergistic business plans and licensing new technology. Codexis will continue to evaluate opportunities to acquire or license new technologies, products or businesses that complement or expand its capabilities, including in the carbon management, water treatment and chemical markets. In addition, it intend to continue to advance its technology platform by investing in research and development.

Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. will be acting as joint book-running managers, with RBC Capital Markets Corporation and Pacific Crest Securities LLC acting as co-managers for the offering. This offering will be made only by means of a prospectus.